Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Perioperative Eltrombopag or Intravenous Immune Globulin for Patients with Immune Thrombocytopenia: A Multicenter Randomized Trial

Donald M. Arnold, MD, Nancy Heddle, MSc, Richard Cook, Cyrus C. Hsia, MDBSc,FRCPC, Mark Blostein, MDFRCPC, Erin Jamula, MSc, Michelle Sholzberg, MDBSc,FRCPC,MSc, Yulia Lin, MD, Jeannine Kassis, MD, Loree Larratt, MD FRCP(C), Sufia Amini, MD, Martin R. Schipperus, Wendy Lim, MD MSc, Prakash Vishnu, MD, Margaret Warner, FRCPC, Julie Carruthers, MLT, B.Com(Hon), Shannon J Lane, MPH, Na Li, PhD, John G. Kelton, MD

Blood (2019) 134 (Supplement_1): 896.

https://doi.org/10.1182/blood-2019-122609

Published: 2019

Journal Articles

Ibrutinib + Obinutuzumab Versus Chlorambucil + Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results from Phase 3 iLLUMINATE

Carol Moreno, MD PhD, Richard Greil, MD, Fatih Demirkan, MD, Alessandra Tedeschi, MD, Bertrand Anz, MD, Loree Larratt, MD, Martin Simkovic, MD PhD, Olga Samoilova, MD, Jan Novak, MD PhD, Dina Ben-Yehuda, MD, Vladimir Strugov, MD, Devinder Gill, MD MRCP, FRCPath, John G. Gribben, Emily Hsu, PhD, Cathy Zhou, MS, Fong Clow, ScD, Danelle F. James, MD MAS, Lori Styles, MD, Ian W. Flinn, MD PhD

Blood (2018) 132 (Supplement 1): 691.

https://doi.org/10.1182/blood-2018-99-111370

Published: 2018

Journal Articles

Prognostic Value of Clone Size in Paroxysmal Nocturnal Hemoglobinuria (PNH) for Thrombotic Events in Untreated Patients in the International PNH Registry

Regis Peffault De Latour, Jaroslaw P. Maciejewski, Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Loree Larratt, MD FRCP(C), Ronald S. Go, MD, David Dingli, MD PhD, Amanda Wilson, PhD, Philippe Gustovic, MD, Aleksandr Kulagin

Blood (2018) 132 (Supplement 1): 1038.

https://doi.org/10.1182/blood-2018-99-111324

Published: 2018

Journal Articles

A Phase 3 Study of Ravulizumab (ALXN1210) Versus Eculizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria Naive to Complement Inhibitors: Results of a Subgroup Analysis with Patients Stratified By Baseline Hemolysis Level, Transfusion History, and Demographics

Ilene C. Weitz, MD, Aleksandr Kulagin, Shinji Nakao, MD PhD, Caroline I. Piatek, MD, Jeffrey Szer, MBBS, Scott T. Rottinghaus, MD, Lori Volles, MD, Andrew I. Damokosh, PhD, Rasha Aguzzi, MS, Loree Larratt, MD, Antonio M. Risitano, MD PhD

Blood (2018) 132 (Supplement 1): 627.

https://doi.org/10.1182/blood-2018-99-110623

Published: 2018

Journal Articles

Analysis of Baseline Clinical Characteristics and Disease Burden in Patients Enrolled in the International Paroxysmal Nocturnal Hemoglobinuria Registry

Hubert Schrezenmeier, MD, Jaroslaw P. Maciejewski, PhD MD FACP, Alexander Roeth, MD, David J. Araten, MD, Yuzuru Kanakura, MD PhD, Loree Larratt, MD FRCP(C), Jamile M. Shammo, MD FASCP, FACP, Amanda Wilson, MPH, PhD, Gilda Shayan, Peter Hillmen, MBChB, PhD

Blood (2017) 130 (Supplement 1): 3488.

https://doi.org/10.1182/blood.V130.Suppl_1.3488.3488

Published: 2017

Journal Articles

Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia

Blood (2017) 129 (5): 553–560.

https://doi.org/10.1182/blood-2016-01-689422

Published: 2017

Journal Articles

A Distributed International Patient Data Registry for Hairy Cell Leukemia

Leslie A. Andritsos, MD, Michael R. Grever, MD, Mirela Anghelina, MD, Claire E Dearden, MD FRCP, FRCPath, Monica Else, MA, MSc, James S. Blachly, MD, Omkar Lele, MS, MBA, Farhad Ravandi, MD, Clive S Zent, MD, James B. Johnston, MD FRCP, Versha Banerji, MD FRCP, Francesco Forconi, MD DM, PhD FRCPath, Anthony D. Ho, MD, Thorsten Zenz, Sascha Dietrich, Judit Demeter, MD PhD, Jacqueline C. Barrientos, MD, Jan A. Burger, MD PhD, Timothy G. Call, MD, Nicholas Chiorazzi, MD, Daniel J. DeAngelo, MD PhD, Julio Delgado, MD, Andrei Fagarasanu, MD PhD, Brunangelo Falini, Alessandro Gozzetti, MD, Jeffrey Jones, MD MPH, Gunnar Juliusson, MD, Eric H. Kraut, MD, Robert J. Kreitman, MD, Loree Larratt, MD, Francesco Lauria, MD, Gerard Lozanski, MD, Emili Montserrat, MD, Sameer A. Parikh, MD, Jae H. Park, MD, Aaron Polliack, MD, Graeme R. Quest, MD MSc, Kanti R. Rai, MD, Tadeusz Robak, MD PhD, Alan Saven, MD, Tamar Tadmor, MD, Martin S. Tallman, MD, Constantine S. Tam, MBBS, Enrico Tiacci, MD, Xavier Troussard, MD PhD, Omar Abdel-Wahab, MD, Pier Luigi Zinzani, MD, PhD, Christopher Heckler, BS, MBA, Philip R.O. Payne, PhD

Blood (2016) 128 (22): 5986.

https://doi.org/10.1182/blood.V128.22.5986.5986

Published: 2016

Journal Articles

Antithymocyte Globulin at Clinically Relevant Concentration Kills Leukemic Blasts

Rosy Dabas, Rachelle Lee, Maria Theresa Servito, Poonam Dharmani Khan, Monica Modi, MD, Tiffany Van Slyke, Joanne Luider, Caylib Durand, Loree Larratt, MD, Joseph Brandwein, MD FRCPC, Andrew Daly, MD FRCPC, Faisal M Khan, PhD D (ABHI), Jan Storek, MD PhD

Blood (2015) 126 (23): 5481.

https://doi.org/10.1182/blood.V126.23.5481.5481

Published: 2015

Journal Articles

The FLAG Chemotherapy Regimen Is an Alternative to Anthracycline Based Therapy for the Treatment of Acute Myeloid Leukemia for Patients with Multiple Co-Morbidities or Preexisting Cardiac Disease

Lalit Saini, MD, Robert Turner, MD, Loree Larratt, MD, Joseph Brandwein, MD, Marlene Ann Hamilton, MD, Anthea Peters, MD MSc, FRCPC, Cynthia M. Wu, MD FRCPC, Nancy Zhu, MD, Jeffery M. Patterson, MD, Lauren Bolster, MD, Michael Mant, MD, Bruce Ritchie, MD, Elena Liew, MD, Imran Mirza, MD FRCPC, Graeme R. Quest, MDMSc, Sunita Gosh, PhD, P.Stat., P.Stat, Irwindeep Sandhu, MD FRCPC

Blood (2014) 124 (21): 961.

https://doi.org/10.1182/blood.V124.21.961.961

Published: 2014

Journal Articles

Bone Marrow Aspirates Alone without a Trephine Biopsy May be Insufficient for the Detection of Residual Leukemia Following Intensive Chemotherapy for the Treatment of Acute Myeloid Leukemia

Lalit Saini, MD, Robert Turner, MD, Loree Larratt, MD, Joseph Brandwein, MD, Marlene Ann Hamilton, MD, Anthea Peters, MD MSc, FRCPC, Cynthia M Wu, MD FRCPC, Nancy Zhu, MD, Jeffery M. Patterson, MD, Lauren Bolster, MD, Michael Mant, MD, Bruce Ritchie, MD, Elena Liew, MD, Imran Mirza, MD FRCPC, Graeme R. Quest, MDMSc, Susan Nahirniak, Sunita Gosh, PhD, P.Stat., P.Stat, Irwindeep Sandhu, MD FRCPC

Blood (2014) 124 (21): 2336.

https://doi.org/10.1182/blood.V124.21.2336.2336

Published: 2014

Journal Articles

PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia

Blood (2014) 124 (3): 420–425.

https://doi.org/10.1182/blood-2013-12-538975

Published: 2014

Includes: Supplemental data

Journal Articles

Very Late Relapse of a Philadelphia Positive Acute Megakaryocytic Leukemia Post Allogenic Bone Marrow Transplant

Jeffery M. Patterson, MD, Lauren Bolster, MD, Marlene Ann Hamilton, MD, Loree Larratt, MD

Blood (2011) 118 (21): 4518.

https://doi.org/10.1182/blood.V118.21.4518.4518

Published: 2011

Journal Articles

Effect of FCGR2A and FCGR3A variants on CLL outcome

Blood (2010) 116 (20): 4212–4222.

https://doi.org/10.1182/blood-2010-03-272765

Published: 2010

Journal Articles

FC-Gamma Receptor (FCGR) 2A and 3A Polymorphisms Do Not Influence the Outcome of Relapsed or Refractory CLL Patients Treated with Rituximab, Fludarabine, and Cyclophosphamide (R-FC) or Fludarabine, and Cyclophosphamide (FC) Alone.

David Dornan, Ph.D, Olivia Spleiss, Ph.D, Ru-Fang T Yeh, PhD, Guillemette Duchateau-Nguyen, PhD, Tadeusz Robak, Sergey I Moiseev, MD, Anna Dmoszynska, MD, Philippe Solal-Celigny, MD, Krzysztof Warzocha, MD, PhD, Javier Loscertales, MD, John Catalano, MD, Boris V Afanasiev, MD, Loree Larratt, MD, Viktor A Rossiev, MD, PhD, Isabelle Bence-Bruckler, MD, FRCPC, Christian H. Geisler, MD, DMSc, Marco Montillo, MD, Michael K. Wenger, MD, Martin Weisser, MD

Blood (2009) 114 (22): 2338.

https://doi.org/10.1182/blood.V114.22.2338.2338

Published: 2009

Journal Articles

Rituximab, Fludarabine, and Cyclophosphamide (R-FC) Prolongs Progression Free Survival in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Compared with FC Alone: Final Results from the International Randomized Phase III REACH Trial

Tadeusz Robak, MD, PhD, Sergey I Moiseev, MD, Anna Dmoszynska, MD, Philippe Solal-Céligny, MD, Krzysztof Warzocha, MD, PhD, Javier Loscertales, MD, John Catalano, MD, Boris V Afanasiev, MD, Loree Larratt, MD, Christian Geisler, MD, DMSc, Marco Montillo, MD, Peter Ganly, BMBCh, PhD, Caroline Dartigeas, MD, András Rosta, MD, PhD, Ann Janssens, MD, Myriam Mendila, MD, Jörg Maurer, Michael K. Wenger, MD

Blood (2008) 112 (11): lba-1.

https://doi.org/10.1182/blood.V112.11.lba-1.lba-1

Published: 2008

Journal Articles

Membrane Type-Matrix Metalloproteinases (MT-MMPs) Are Expressed in Acute Myeloid Leukemia Cells and Are Upregulated by TNF-α.

Neeta Shirvaikar, MSc, Ali Jalili, PhD, Sara Ilnitsky, BSc, Loree Larratt, MD, Imran Mirza, MD, Anna Janowska-Wieczorek, MD, PhD

Blood (2007) 110 (11): 2853.

https://doi.org/10.1182/blood.V110.11.2853.2853

Published: 2007

Journal Articles

TNF-α Stimulates Matrix Metalloproteinase Expression in Myelodysplastic Syndromes (MDS): Therapeutic Potential for Inhibitors of TNF-α and MMPs.

A. Janowska-Wieczorek, MD, PhD, Leah A. Marquez-Curtis, PhD, Kenton Gan, Loree Larratt, MD, Anthony Woods, MD

Blood (2005) 106 (11): 3447.

https://doi.org/10.1182/blood.V106.11.3447.3447

Published: 2005

Journal Articles

Adult Matched Sibling Blood Cell Transplants (BCT) after Myeloablative Conditioning Incorporating Daily Intravenous (IV) Busulfan (BU) and Low-Dose Antithymocyte Globulin (ATG): Outcomes with Particular Respect to Transplant-Related Mortality (TRM) in 140 Patients.

James A. Russell, FRCP, Ahsan M. Chaudhy, MD, Oluyeme Jeje, MD, Diana Quinlan, RN, Douglas Stewart, MD, Donald Morris, MD, Nizhar J. Bahlis, MD, Lynne Savoie, MD, Christopher B. Brown, MD, Loree Larratt, MD, Michelle Geddes, MD, A. Robert Turner, MD

Blood (2004) 104 (11): 2313.

https://doi.org/10.1182/blood.V104.11.2313.2313

Published: 2004

Journal Articles

Antitumor Activity of Bortezomib (PS-341; Velcade) in a Phase II Study of Patients with Previously Untreated or Treated Waldenstrom’s Macroglobulinemia (WM).

Christine I. Chen, MD, Darrell White, MD, C. Tom Kouroukis, MD, A. Keith Stewart, MD, Kang Howson-Jan, MD, Loree Larratt, MD, Jean Powers, Elizabeth Eisenhauer, MD

Blood (2004) 104 (11): 3278.

https://doi.org/10.1182/blood.V104.11.3278.3278

Published: 2004

Journal Articles

Adult Recipients of Matched Related Donor Blood Cell Transplants (BCT) Given Pretransplant Low-Dose Antithymocyte Globulin (ATG) Have Less Chronic Graft-Versus-Host Disease (cGVHD) and Transplant-Related Mortality (TRM): A Matched Pair Analysis.

James A. Russell, FRCPE, A. Robert Turner, MD3, Loree Larratt, MD, Ahsan M. Chaudhry, MD, Oluyeme Jeje, MD, Don Morris, MD, Christopher B. Brown, MD, Lynne Savoie, MD, Nizhar Bahlis, MD, Diana Quinlan, RN, Douglas Stewart, MD

Blood (2004) 104 (11): 2250.

https://doi.org/10.1182/blood.V104.11.2250.2250

Published: 2004

NARROW

Perioperative Eltrombopag or Intravenous Immune Globulin for Patients with Immune Thrombocytopenia: A Multicenter Randomized Trial

Ibrutinib + Obinutuzumab Versus Chlorambucil + Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results from Phase 3 iLLUMINATE

Prognostic Value of Clone Size in Paroxysmal Nocturnal Hemoglobinuria (PNH) for Thrombotic Events in Untreated Patients in the International PNH Registry

A Phase 3 Study of Ravulizumab (ALXN1210) Versus Eculizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria Naive to Complement Inhibitors: Results of a Subgroup Analysis with Patients Stratified By Baseline Hemolysis Level, Transfusion History, and Demographics

Analysis of Baseline Clinical Characteristics and Disease Burden in Patients Enrolled in the International Paroxysmal Nocturnal Hemoglobinuria Registry

Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia

A Distributed International Patient Data Registry for Hairy Cell Leukemia

Antithymocyte Globulin at Clinically Relevant Concentration Kills Leukemic Blasts

The FLAG Chemotherapy Regimen Is an Alternative to Anthracycline Based Therapy for the Treatment of Acute Myeloid Leukemia for Patients with Multiple Co-Morbidities or Preexisting Cardiac Disease

Bone Marrow Aspirates Alone without a Trephine Biopsy May be Insufficient for the Detection of Residual Leukemia Following Intensive Chemotherapy for the Treatment of Acute Myeloid Leukemia

PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia

Very Late Relapse of a Philadelphia Positive Acute Megakaryocytic Leukemia Post Allogenic Bone Marrow Transplant

Effect of FCGR2A and FCGR3A variants on CLL outcome

FC-Gamma Receptor (FCGR) 2A and 3A Polymorphisms Do Not Influence the Outcome of Relapsed or Refractory CLL Patients Treated with Rituximab, Fludarabine, and Cyclophosphamide (R-FC) or Fludarabine, and Cyclophosphamide (FC) Alone.

Rituximab, Fludarabine, and Cyclophosphamide (R-FC) Prolongs Progression Free Survival in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Compared with FC Alone: Final Results from the International Randomized Phase III REACH Trial

Membrane Type-Matrix Metalloproteinases (MT-MMPs) Are Expressed in Acute Myeloid Leukemia Cells and Are Upregulated by TNF-α.

TNF-α Stimulates Matrix Metalloproteinase Expression in Myelodysplastic Syndromes (MDS): Therapeutic Potential for Inhibitors of TNF-α and MMPs.

Adult Matched Sibling Blood Cell Transplants (BCT) after Myeloablative Conditioning Incorporating Daily Intravenous (IV) Busulfan (BU) and Low-Dose Antithymocyte Globulin (ATG): Outcomes with Particular Respect to Transplant-Related Mortality (TRM) in 140 Patients.

Antitumor Activity of Bortezomib (PS-341; Velcade) in a Phase II Study of Patients with Previously Untreated or Treated Waldenstrom’s Macroglobulinemia (WM).

Adult Recipients of Matched Related Donor Blood Cell Transplants (BCT) Given Pretransplant Low-Dose Antithymocyte Globulin (ATG) Have Less Chronic Graft-Versus-Host Disease (cGVHD) and Transplant-Related Mortality (TRM): A Matched Pair Analysis.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only